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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
Progressive Muscle Relaxation (PMR) is an effective adjunctive therapy in reducing depression
symptoms in cancer patients.
STUDY DESIGN: Systematic review of three randomized controlled trials (RCTs), one being
modified and used a case series, from peer reviewed journals, published in 2015, 2016 and 2018.
DATA SOURCES: The studies compare the effectiveness of PMR versus other therapies such
as routine nursing care and weekly visits with psychologists. All studies were found using
PubMed and Cochrane Library.
OUTCOMES MEASURED: Depression symptoms perceived by the patient and measure by the
Zung self-rating depression scale, Beck Depression Inventory and Hospital Anxiety and
Depression scale.
RESULTS: In the single-blind RCT conducted by Charalambous, et al., there was a reduction of
depression symptoms with a mean change in baseline of 7.7. These results were statistically
significant with a p-value of <0.0001. In the RCT, being used as a case series, conducted by Liao
et al., there was a reduction of depression symptoms with a mean change in baseline of 2.86.
These results were statistically significant with a p-value of <0.05. In the single-blind RCT
conducted by Zhou et al., showed a statistically significant decrease in posttest depression
symptoms with a p-value <0.0001 and an F score of 20.31.
CONCLUSION: The three studies in this systematic review showed a statistically significant
decrease in depression symptoms in the cancer patients studied; however, the results remain
inconclusive as they could be skewed by the adjunct therapies of music listening and guided
imagery. Further research needs to be conducted in order to prove the effects are truly from PMR
as an adjunct, such as using PMR and music therapy or guided imagery as the treatment group,
and music therapy or guided imagery alone as the control group.
KEYWORDS: Progressive Muscle Relaxation, Cancer, Depression
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INTRODUCTION
Cancer is an unregulated division of cells in tissues that have the ability to invade
surrounding tissues and organs and metastasize to other areas in the body. Cancer does not only
impact the body physically but can have a profound impact mentally and emotionally. Along
with many other risk factors, those who undergo a significant life event, such as a cancer
diagnosis, are at high risk for developing depression.1,2
As life expectancies continue to grow, cancer rates will concomitantly rise as well. In
2020, approximately 1.8 million people will be diagnosed with cancer in the United States and
606,500 will die because of this disease.1 Due to the various types of cancer, mortality rates and
age distributions, depression rates among cancer patient are difficult to define. However, one
study showed that about 15-25% of patients with cancer will experience depression.3 Cancer
patients suffering with depression accumulate 113% more health care charges yearly compared
to patients without depression.4 It is difficult to accurately identify how many health care visits
patients with cancer and depression accrue, but in 2016, cancer accounted for 24.7 million
healthcare visits and 9.3% of patients had a depression diagnosis on their medical chart. 5
Depression does not discriminate and can virtually affect anyone. There are no discrete
criteria regarding who it affects, however, there are conditions that may predispose an individual.
Family history, significant life events, environmental factors such as socioeconomic status or
child abuse, personality types and alterations in brain chemistry are risk factors for depression.
Depression is not just being sad or down, but a coalition of symptoms that affects how one
thinks, lives and makes decisions. The gold standard of treatment for depression is the use of
selective serotonin reuptake inhibitors (SSRIs).6 Among these are escitalopram, sertraline,
fluoxetine, citalopram and paroxetine. Selective norepinephrine reuptake inhibitors (SNRIs),
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tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and bupropion are
other medications used if there are contraindications to SSRIs.6 Cognitive behavioral therapy
(CBT) is often used in conjunction with medications, focusing on a problem-solving approach.6
In refractory depression, electroconvulsive therapy (ECT) can be used.6
Progressive muscle relaxation (PMR) is an adjunctive therapy often used to cope with
mental health symptoms.7 It works by alternatively tensing and relaxing certain muscle groups in
hopes that patients will benefit by acknowledging when they are in certain situations that make
them tense and relax accordingly.7 PMR is being further investigated in cancer patients due to
the fact that in prior research, this population has had improved mental health symptoms with the
use of psychological intervention.8
OBJECTIVE
The objective of this selective evidence-based medicine (EBM) review is to determine
whether PMR is an effective adjunctive therapy in reducing depression symptoms in cancer
patients.
METHODS
The clinical question posed sought to investigate PMR; therefore, PMR with either GI,
CM or music listening used by primary researchers were considered for this review. The
intervention method in this study was PMR with Guided Imagery (GI) or Chinese Medicine five
element music (CM) or music listening, in comparison to routine nursing care, and weekly
meetings with the health center psychologist. Improvement in depression symptoms based on
their severity of symptoms at baseline and after treatment were determined for effectiveness of
therapies. The studies selected for this systematic review consisted of three RCTS, with Liao et
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al. being used as a case series, to investigate the effect of PMR on depression symptoms in
cancer patients.
The three articles included were peer reviewed and published in journals using the
following databases: Cochrane Library and PubMed. The keywords used to search articles
pertaining to the topic were PMR, cancer, depression, RCT and all articles were published in
English. These articles were selected based on their relevance to the topics and patient oriented
evidence that matters (POEMs). The criteria of the articles researched included RCTs, English
and human studies and excluded animal studies and children’s studies. The summary of statistics
was reported using an F score and the mean change from baseline. The demographics and
characteristics of each study is shown in Table 1.
OUTCOMES MEASURED
The outcome of depression symptoms was measured by three separate entities. The Beck
Depression Inventory-II (BDI-II) is a 21 item self-report measure on scale of zero (no depression
symptoms) and three (severe depression symptoms). 7 A score of 0-13, 14-19, 20-28 or greater
than 29, suggest minimal, mild, moderate and severe depression respectively.7 The Hospital
Anxiety and Depression scale (HADS) is a seven-question survey with answers ranging from
zero to three.8 A score of 0-7, 8-10, or 11-21 indicate no depression, borderline and depression
respectively.8 Lastly, the Zung Self-Rating Depression Scale (ZSDS), a 20 item self-report
measure on a scale of zero (no depression symptoms) and four (severe depression symptoms). 9 A
score of below 50, 50-59, 60-69 and greater than 70 indicate no depression, minimal to mild,
moderate to marked and severe to extreme depression respectively.9
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RESULTS
A single blinded RCT was conducted in the country of Cyprus by Charalambous et al.,
where 236 participants were randomly assigned by a 1:1 ratio to a control group or an
intervention group.7 Participants included in this study were over 18 years of age with an active
breast or prostate cancer diagnosis and were receiving chemotherapy. Further inclusion and
exclusion criteria are mentioned in Table 1. Out of the 236 participants, 208 completed the study.
Table 1. Demographics and Characteristics of Included Studies

Study

Type

# Pts

Age

Inclusion Criteria

Exclusion
Criteria

Charala
mbous,
et al.
20167

RCT

236

>18
yrs
old

Dx of breast or
prostate CA,
receiving chemo,
experiencing fatigue,
pain, N/V, depression
or anxiety

4 weekly
supervised
and daily
unsupervised
sessions of
PMRT

Liao et
al. 20188

RCT
(using
as case
series)

30

> 18 Pts histologically and
yrs
cytologically
old confirmed as cancer
regardless of tumor
type/disease staging
HADS score between
7-15
Primary school
education and
Karnofsky
performance status no
less than 60

Patients with
28
visual/hearing/
cognitive
impairment,
xerostomia
and/or oral
mucositis
Patients with
1
psychiatric
disease,
intellectual
disability or
deafness and
expected
survival <3
months

Zhou et
al. 20159

RCT

170

2565
yrs
old

Patients with
0
voice sensitive
epilepsy, not
preferred to
music
listening or
refused to give
written
consent

PMRT for 30
minutes once
in the
morning and
once at
nighttime
until
discharge

Female, Dx of breast
cancer with arranged
radical mastectomy

W/D Interventions

20 minutes of
PMRT
followed by
20 minutes of
CM five
element
music
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Participants in the intervention group, received four weekly supervised and daily unsupervised
sessions of PMR followed by a guided imagery session (GI) and a control group, who had
weekly meetings with the health center psychologist. 7 Patients were assessed at baseline and the
end of four weeks using the Beck Depression Inventory-II (BDI-II) scale.7
After four weeks of treatment, the mean change from baseline in the intervention group
was 7.7 with a p-value of <0.0001.7 Shown in Table 2 below, patients in the intervention group
mean baseline score on the BDI-II was 27.3  7.6, while the mean follow up score was 19.6 
8.6. In comparison, patients in the control group saw a mean change in baseline of -7.0 with a pvalue of <0.0001.7 In accordance with the BDI-II, 35 patients in the intervention group were
classified as moderately depressed at baseline.7 This number decreased to 15 patients following
the four weeks of intervention.7 In comparison, the incidence of moderate depression increased
by 42% in the control group, p-value 0.02.7 These results show a statistically significant decrease
in depression symptoms with the use of PMR followed by GI.7 There was no mention of adverse
events occurring in this study.
Table 2. BDI-II Mean  SD Change in Depression Symptoms at Baseline and 4 Weeks PostIntervention Between Control and Intervention Groups (Charalambous et al. 20167)
Baseline
Post-Intervention
∆
p-value
PMR + GI
<0.0001
27.3  7.6
19.6  8.6
7.7  6.9
Psychologist
<0.0001
28.2  9.4
35.2  12.0
-7.0  7.8
A second study was conducted in two hospitals in Beijing, China by Liao et al. Thirty
participants were assigned to a treatment group. One participant was lost to follow up. Refer to
the methods section regarding the use of this RCT as a case series.8 Participants were required to
be over 18 years of age, have an active cancer diagnosis, primary school education, and a
Karnofsky Performance Status score of no less than 60.8 Further inclusion and exclusion criteria
are mentioned in table 1. The intervention group received 20 minutes of PMR followed by 20

Nolan | PMR for Depression in Cancer Patients

6

minutes of Chinese Medicine Five Element Music.8 The group was then assessed at baseline and
after eight weeks of therapy using the Hospital Anxiety and Depression Scale (HADS). 8
After eight weeks of treatment, the mean change from baseline was 2.86 with a p-value
of <0.05.8 Demonstrated in Table 3, patients initially scored 6.55  3.08 on the HADS at baseline
and decreased to 3.68  1.97 after eight weeks.8 The use of PMR and CM showed a statistically
significant decrease in depression scores after eight weeks of treatment in comparison to
baseline.8 There was no mention of adverse events occurring in this study.
Table 3. Hospital Anxiety & Depression Scale Mean  SD Change in Symptom Scores at
Baseline and at 8 Weeks of Treatment (Liao et al. 20188)
Baseline
8 Weeks
∆
p-value
PMR + CM
2.86
<0.05
6.55  3.08
3.69  1.97
Zhou et al. conducted a single-blind RCT in Xi’an, China, in which 170 participants were
randomly assigned to a control group or an intervention group and all of them completed the
study.9 To be included in this study, participants required an active breast cancer diagnosis and
have undergone radical mastectomy. Further exclusion criteria are mentioned in table 1.
Participants in the intervention group simultaneously received PMR and music listening for 30
minutes in the morning, and 30 minutes at night.9 Patients in the control group received routine
nursing care which included vital signs, tube drainage, functional exercise on the side of surgery,
and post op complication monitoring.9 Patients were assessed using the Zung Self-Rating
Depression Scale (ZSDS) at baseline and post mastectomy, until discharge from the hospital.9
After treatment, the control groups pretest depression scores decreased from 38.01  6.65
to posttest depression scores of 33.40  5.30.9 For the intervention group, the pretest depression
scores decreased from 37.47  5.66 to posttest depression scores of 30.21  3.3.9 The PMR with
music listening showed a statistically significant decrease in depression symptoms with a p-value
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of 0.001 (Table 4).9 With this data, an F score was calculated as 20.31.9 There was no mention
of adverse events occurring in this study.
Table 4. Comparison of Pre-test and Post-Test Depression Scores on the Zung Self-Rating
Depression Scale Between Intervention and Control Groups (Zhou et al. 20159)
Pre-test
Post-test
F Score
P-value
(Univariate
analysis)
PMR + Music
37.47  5.66
30.21  3.31
20.31
<0.001
Nursing Care
38.01  6.65
33.40  5.30
DISCUSSION
Though there have been outstanding improvements in diagnosing and treating cancer, it
is still a deadly disease that has a profound impact both physically and mentally. It requires
many visits to healthcare offices and hospitals which can eventually take a toll on patients. This
three-study systematic review evaluates the efficacy of PMR as an adjunctive therapy in hopes to
reduce depression symptoms in cancer patients. As mentioned above, PMR aims at reducing
tension throughout the body by contracting and then relaxing certain muscle groups in order,
which aims at reducing mental health symptoms.7 Charalambous et al. and Liao et al.
demonstrated a decrease in depression symptoms with a mean change in baseline of 7.7 and 2.89
respectively.7,8 Both studies showed statistical significance with p-values of <0.0001 and <0.05
respectively.7,8 Zhou et al. utilized a general linear model with univariate analysis and calculated
a statistically significant F score of 20.31 (p<0.001) which showed a statistically significant
decrease in the intervention group compared to the control group.9 Although these three studies
had a statistically significant reduction in depression symptoms, it is not clear whether PMR
directly played a role in this reduction.
The three studies in this review had numerous limitations. In Charalambous et al.,
creating a double-blind study was not possible due to the techniques of using PMR and GI.
During the unsupervised sessions, researchers were not confident that patients were in an
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environment free of external stimuli or completed the full sessions.7 This study took place in the
country of Cyprus and consisted of only breast and prostate cancer patients which limits the
generalizability. In Liao et al., the absence of a control group and small sample size of patients,
29, limited the study. The generalizability was also limited due to one of the two hospitals used
in this study, being a geriatric hospital. Finally, the study conducted by Zhou et al, did not
contain the physiologic data regarding depression and the reduction in symptoms may have been
attributed to increased attention towards the intervention group.9 Furthermore, the
generalizability of the study was low due to its location in only one province in China, and all
participants being female with breast cancer after radical mastectomy.
As therapies continue to improve and life expectancies rise, cancer rates will increase as
well along with the myriad of symptoms cancer entails, such as depression. PMR is a technique
that was developed in the 1920s, initially for anxiety, but its indications have expanded greatly
since its birth.10 It is a form of therapy that focuses on the voluntary and thoughtful contraction
and subsequent relaxation of 14 different muscle groups.10 The aim of this therapy is to teach the
patient to recognize situations when they are tense and to relax accordingly, leading to the
improvement of their mental health.10 PMR is a technique that takes practice and may not yield
results immediately. When recommending PMR to patients, it is important to assess their
motivation to determine whether PMR may benefit them.
CONCLUSION
The aim of this systematic review was to determine whether PMR is effective as an
adjunctive therapy in reducing depression symptoms in cancer patients. Based on the analysis of
the three studies, the results of this review are inconclusive. Although the groups treated with
PMR as an adjunct showed a statistically significant reduction in depression symptoms 7,8,9, it
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cannot be determined if PMR played a part in this reduction. In order to further evaluate the
efficacy of PMR, more specific studies should be conducted evaluating PMR as an adjunct. For
example, using PMR paired with music therapy or guided imagery as the treatment group, and
music therapy or guided imagery alone as the control group. By doing this, we will be able to
further evaluate the effect PMR plays in reducing depression symptoms. Furthermore, increasing
sample sizes, extending treatment time, and ensuring the quality of the PMR may help to
strengthen the validity of future studies. Cancer is a devastating disease that can profoundly
impact one’s mental health and using adjunctive therapies such as PMR may help alleviate some
of these symptoms which in turn, will improve patient’s lives.
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